MYCO.CN

VANCOUVER, BC, Jan. 14, 2021 - Trading resumes in:Company: Mydecine Innovations Group Inc.CSE Symbol: MYCOAll Issues: OuiResumption (ET): 12:00 PMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC ... Read More...

DENVER, Jan. 28, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled... Read More...

DENVER, Jan. 22, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has been included in the first-ever Psychedelics Exchanged... Read More...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESMydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for ma... Read More...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/DENVER, Jan. 14, 2021 - Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative natu... Read More...

Company files seven provisional patent applications with United States Patent and Trademark OfficeDENVER, Jan. 07, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative natur... Read More...

DENVER, Jan. 05, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled... Read More...

Leading FDA consultancy firm to advise on drug development and clinical trial pipelineDENVER, Dec. 15, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic m... Read More...

Mydecine completes harvest and is preparing to export 20 kilograms of psilocybin mushrooms from Jamaica to Canada for increased global supply scale of cGMP nature-sourced psilocybinDENVER, Dec. 08, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company com... Read More...

KCSA to provide Public Relations and Social Media CounselNEW YORK, Nov. 6, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced th... Read More...

VANCOUVER, British Columbia, Oct. 19, 2020 -- MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the ... Read More...

VANCOUVER, British Columbia, Oct. 07, 2020 -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine"), is pleased to announce its wholly-owned subsidiary, NeuroPharm Inc. ("NeuroPharm”), has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering composition of mat... Read More...

Picture 1Figure 1Figure 1DENVER, Sept. 30, 2020 -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine") is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital telehealth mobile application for mental coaching and wellbeing, has officially launched and is available for download today:... Read More...

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/42c4893d-6232-4d13-9d58-b3098cc222bbDENVER, Sept. 24, 2020 --  Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine"), is pleased to announce that its subsidiary Mindleap Health’s (“Mindleap” ) telehealth platform wil... Read More...

DENVER, Sept. 15, 2020 -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine"), today announced the Company has formed a special committee to evaluate a number of options to increase shareholders value.Topics that the special committee will discuss include, but limited to, a potential spin out of certain company ... Read More...

Being Facilitated Under a Schedule 1 Health Canada Dealer’s LicenseDENVER, Aug. 18, 2020 -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine™") is pleased to announce it is the first organization to exercise its cGMP(₁) capabilities under a special license to legally produce, transfer, sell, and export pharma... Read More...